SIRT3 and prostate cancer: To provide additional evidence in support of this notion, we performed immunohistochemical (IHC) staining of SIRT3 in primary tumors of prostate cancer patients (n=109, of which 32 biopsies were benign tissues, and 77 biopsies were tumor tissues).